Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Expenses: 2020-2023

Historic Accumulated Expenses for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $3.4 million.

  • Candel Therapeutics' Accumulated Expenses fell 22.86% to $3.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.4 million, marking a year-over-year decrease of 22.86%. This contributed to the annual value of $4.7 million for FY2022, which is 37.38% up from last year.
  • As of Q3 2023, Candel Therapeutics' Accumulated Expenses stood at $3.4 million, which was down 1.89% from $3.5 million recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Accumulated Expenses registered a high of $4.7 million during Q4 2022, and its lowest value of $2.9 million during Q1 2023.
  • Moreover, its 3-year median value for Accumulated Expenses was $3.5 million (2021), whereas its average is $3.7 million.
  • In the last 5 years, Candel Therapeutics' Accumulated Expenses skyrocketed by 37.38% in 2022 and then declined by 22.86% in 2023.
  • Candel Therapeutics' Accumulated Expenses (Quarterly) stood at $3.1 million in 2020, then grew by 9.42% to $3.4 million in 2021, then surged by 37.38% to $4.7 million in 2022, then declined by 22.86% to $3.4 million in 2023.
  • Its Accumulated Expenses was $3.4 million in Q3 2023, compared to $3.5 million in Q2 2023 and $2.9 million in Q1 2023.